Jazz Pharmaceuticals plc Stock
Price
Target price
€138.80
€138.80
0.800%
1.1
0.800%
€171.00
30.01.26 / Tradegate
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Jazz Pharmaceuticals plc Stock
Jazz Pharmaceuticals plc gained 0.800% compared to yesterday.
The stock is an absolute favorite of our community with 39 Buy predictions and no Sell predictions.
As a result the target price of 171 € shows a positive potential of 23.2% compared to the current price of 138.8 € for Jazz Pharmaceuticals plc.
Pros and Cons of Jazz Pharmaceuticals plc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Jazz Pharmaceuticals plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | 0.800% | -2.801% | -3.878% | 15.763% | -3.878% | -3.370% | 7.597% |
| Repligen Corp. | -2.950% | -8.297% | -10.543% | -22.581% | -10.543% | -27.378% | -26.359% |
| Opko Health Inc. | 0.200% | -4.289% | -7.081% | -27.394% | -7.081% | -17.829% | -79.469% |
| Amicus Therapeutics Inc. | -1.680% | -3.306% | -2.500% | 27.174% | -2.500% | -0.780% | -24.516% |
Comments
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
